Quebec Cancer Treatment Cost
- A Quebec man is appealing too the province to cover the cost of a potentially life-extending treatment for an aggressive form of brain cancer.
- Mathieu Bolduc, 28, is battling a glioblastoma, a rare cancer affecting approximately 150 new patients in Quebec annually.
- Bolduc recalls the sudden onset of his condition: I suddenly felt very strong dizziness and I could no longer keep balance.
Quebec patient Seeks Coverage for Brain Cancer Treatment
Table of Contents
- Quebec patient Seeks Coverage for Brain Cancer Treatment
- Quebec Patient’s Plea for Brain Cancer Treatment Coverage: A Q&A
- what is Glioblastoma (GBM)?
- What is Optune and How Does it Work?
- How Effective is Optune in Treating GBM?
- What are the Survival Rate statistics with and without Optune?
- What are the Costs Associated with Optune Treatment?
- Is the Quebec Government Covering Optune Treatment?
- Why is Optune not Covered by Quebec’s Public Health Insurance?
- What are the Alternatives for Patients Who Cannot afford Optune?
- What are the Key Challenges in GBM Treatment?
A Quebec man is appealing too the province to cover the cost of a potentially life-extending treatment for an aggressive form of brain cancer.
Mathieu Bolduc, 28, is battling a glioblastoma, a rare cancer affecting approximately 150 new patients in Quebec annually. A year ago, Bolduc was active, but now focuses on maintaining normalcy in his daily life.
Bolduc recalls the sudden onset of his condition: I suddenly felt very strong dizziness and I could no longer keep balance. I couldn’t really walk properly and I had a lot of trouble talking.
His symptoms rapidly worsened, leading to hospitalization and the diagnosis of a grade four tumor causing a cerebral hemorrhage.
Basically, my life wholly changed overnight.
Bolduc has undergone surgery, radiation, and chemotherapy. His medical team has recommended Optune, a device that uses electric fields to target cancer cells.
Survival Rate Increase
Dr.David Roberge, a radio-oncologist, participated in a study across 14 countries, including Canada, examining Optune’s effectiveness.
Among the hundreds of patients participating in the trial, those who received treatment live longer than those who have not received it.
The study indicated that the five-year survival rate more than doubled with the device’s use.
Roberge stated that the study revealed that the chances of survival five years after the diagnosis are 5% without the device and 13% with it,
adding that it is the only new treatment for glioblastoma with positive results in 20 years.
However, the treatment costs up to $27,000 per month, a cost Quebec’s public health insurance, RAMQ, has so far declined to cover.
I mean, it gave me hope until I realize that I could not afford it,
Bolduc said.
Roberge expressed his frustration, stating, If I don’t tell you about it, I don’t do my job. But if I tell you about it and then you feel like you have to mortgage your home to get it, or you can’t get it, and you live with the frustration of knowing that there is something you can’t get. It puts people in a tough situation.
Quebec’s Stance
Health Canada approved Optune in 2022.The Quebec Health Institute evaluated the treatment in 2023 but did not recommend coverage, citing high costs and monitoring concerns.
Roberge questions why the Ministry of Health has not attempted to negotiate the price with Novocure, the device’s manufacturer.
The Ministry of Health cites uncertainties regarding the device’s use within the healthcare system.
A ministry spokesperson stated, certain conditions preliminary to public coverage are not yet met. however, the ministère remains on the lookout for new data and information on the Optune system which could justify a reassessment of this technology in the future.
The spokesperson added that solutions are being considered for patients with glioblastoma.
Bolduc’s family has pooled their savings, raising over $50,000 to afford the treatment.
People have no choice, aren’t they?
Bolduc said. It is either we take it, or we will die after two years.
While the funds will only cover a few months of treatment, he hopes it will allow him to spend more time with his loved ones.
Quebec Patient’s Plea for Brain Cancer Treatment Coverage: A Q&A
Glioblastoma (GBM), a particularly aggressive form of brain cancer, presents significant challenges for patients and their families. This article delves into the story of a Quebec man seeking access to a possibly life-extending treatment, Optune, and provides answers to common questions about GBM and its treatment.
what is Glioblastoma (GBM)?
Glioblastoma multiforme (GBM) is a rare and aggressive type of brain cancer that develops from glial cells in the central nervous system. It is the most common form of brain cancer in Canada. Each year, approximately 150 new patients are diagnosed with GBM in Quebec. Symptoms can appear suddenly and rapidly worsen, leading to significant changes in a patient’s life.
What is Optune and How Does it Work?
Optune is a wearable, portable medical device approved by Health Canada for the treatment of newly diagnosed and recurrent glioblastoma in adults. It utilizes Tumor treating Fields (TTFields), which are electric fields designed to disrupt the division of cancer cells. [1] For newly diagnosed GBM,Optune is used in conjunction with the chemotherapy drug temozolomide (TMZ). [3]
How Effective is Optune in Treating GBM?
Clinical studies, including trials conducted in Canada and 13 other countries, have demonstrated Optune’s effectiveness.Patients treated with Optune have shown improved survival rates. according to Dr. David Roberge, a radio-oncologist, the five-year survival rate more than doubled with the use of Optune.
What are the Survival Rate statistics with and without Optune?
Research shows a significant enhancement in survival rates with the use of Optune:
Without Optune: Approximately a 5% chance of survival five years after diagnosis.
With Optune: approximately a 13% chance of survival five years after diagnosis.
What are the Costs Associated with Optune Treatment?
The treatment with Optune can be expensive, costing up to $27,000 per month. This high cost has created a barrier for some patients, including Mathieu Bolduc, who is seeking public health insurance coverage in Quebec.
Is the Quebec Government Covering Optune Treatment?
Currently, Quebec’s public health insurance (RAMQ) has not approved coverage for Optune. The Quebec health institute assessed the treatment in 2023 but did not recommend coverage, citing high costs and monitoring concerns. The Ministry of Health is currently reviewing new data to reassess the technology.
Why is Optune not Covered by Quebec’s Public Health Insurance?
The Ministry of Health cites uncertainties regarding the device’s use within the healthcare system and the need for certain conditions to be met before public coverage is approved.
What are the Alternatives for Patients Who Cannot afford Optune?
Due to the high cost of the treatment, finding affordable treatment options can be challenging for patients. Some may turn to fundraising efforts, such as the one undertaken by Mathieu Bolduc’s family, who raised over $50,000.
What are the Key Challenges in GBM Treatment?
The main challenges in GBM treatment include:
Aggressiveness of the Cancer: GBM is a rapidly progressing cancer.
High Treatment Costs: The costs of innovative treatments like Optune can be prohibitive.
* Access to Treatment: Gaining access to potentially life-extending treatments can be challenging.